UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8

Benzinga Newsdesk www.benzinga.com Neutral 78.8%

Neg 0% Neu 78.8% Pos 0%

UBS analyst Alice Nettleton initiates coverage on Evommune (NYSE:EVMN) with a Neutral rating and announces Price Target of $8.